1. Home
  2. DNUT vs PRTA Comparison

DNUT vs PRTA Comparison

Compare DNUT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krispy Kreme Inc.

DNUT

Krispy Kreme Inc.

HOLD

Current Price

$3.67

Market Cap

585.5M

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$11.20

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNUT
PRTA
Founded
1937
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
585.5M
539.9M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
DNUT
PRTA
Price
$3.67
$11.20
Analyst Decision
Hold
Buy
Analyst Count
5
9
Target Price
$4.15
$19.00
AVG Volume (30 Days)
1.9M
355.8K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,522,616,000.00
$814,000.00
Revenue This Year
$0.55
$1,111.38
Revenue Next Year
$3.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.58
$4.32
52 Week High
$5.73
$11.69

Technical Indicators

Market Signals
Indicator
DNUT
PRTA
Relative Strength Index (RSI) 50.19 60.59
Support Level $3.09 $10.27
Resistance Level $3.87 $11.61
Average True Range (ATR) 0.24 0.40
MACD -0.02 -0.02
Stochastic Oscillator 13.61 67.95

Price Performance

Historical Comparison
DNUT
PRTA

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: